Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMZ002 vs vigabatrin for treatment of infantile spasms (Phase 3)
2021-003015-26Phase 3Terminated
- Sponsor
- Amzell B.V.
- Start
- Oct 2021
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of AMZ002 in West syndrome (2 arms), sponsored by Amzell B.V. Primary endpoint: Primary Efficacy Endpoints. Started Oct 2021; status: terminated.
02
Drugs
AMZ002
03
Conditions
West syndrome
Beyond the preview
Go deeper on 2021-003015-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003015-26.